EARLY SYMPTOMATIC THERAPY WITH ALGINATES AND ANTACIDS IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE

Download full text PDF
Issue: 
2
Year: 
2016

Professor V. Chukanov (1), MD; Professor E. Onuchina (2), MD; Professor E. Kasparov (1), MD; S. Brikova (3); A. Vasyutin (1), Candidate of Medical Sciences 1 -Research Institute of Medical Problems of the North, Krasnoyarsk 2 -Irkutsk State Medical Academy of Postgraduate Education, Irkutsk 3 -Clinical Hospital for War Veterans, Irkutsk

A randomized clinical trial enrolling 86 patients with gastroesophageal reflux disease (GERD) has demonstrated the higher efficacy of an alginate than that of an aluminum and magnesium antacid in relieving the symptoms of GERD and dyspepsia.
Keywords: 
alginates
antacids
gastroesophageal reflux disease
dyspepsia

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. El-Serag H., Sweet S., Winchester C. et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review // Gut. – 2014; 63 (6): 871–80.
  2. Butorin N.N., Bichurina T.B., Tsukanov V.V. i dr. Rasprostranennost' i klinicheskie aspekty pischevoda Barretta u naselenija Vostochnoj Sibiri // Ter. arh. – 2013; 1: 62–5.
  3. Everhart J., Ruhl C. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases // Gastroenterology. – 2009; 136 (2): 376–86.
  4. Kahrilas P., Keefer L., Pandolfino J. Patients with refractory reflux symptoms: What do they have and how should they be managed? // Neurogastroenterol. Motil. – 2015; 27 (9): 1195–201.
  5. Tsukanov V.V., Onuchina E.V., Vasjutin A.V. i dr. Taktika vedenija bol'nyh gastroezofageal'noj refljuksnoj bolezn'ju s vnepischevodnymi sindroma-mi // Farmateka. – 2015; 6: 11–4.
  6. Tsukanov V.V., Onuchina E.V., Kasparov E.V. i dr. Opyt dlitel'noj tera pii patsientov s pischevodom Barretta // Farmateka. – 2015; 2: 62–5.
  7. Sharma P., Katzka D., Gupta N. et al. Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium // Gastroenterology. – 2015; 149 (6): 1599–606.
  8. Tsukanov V.V., Onuchina E.V., Vasjutin A.V. i dr. Klinicheskie aspekty gastroezofageal'noj refljuksnoj bolezni u lits pozhilogo vozrasta: rezul'-taty 5-letnego prospektivnogo issledovanija // Ter. arh. – 2014; 2: 23–6.
  9. Lundell L., Dent J., Bennett J. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification // Gut. – 1999; 45 (2): 172–80.
  10. Vakil N., van Zanden S., Kahrilas P. et al. The Monreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus // Am. J. Gastroenterol. – 2006; 101 (8): 1900–20.
  11. Locke G., Talley N., Weaver A. et al. A new questionnaire for gastroesophageal reflux disease // Mayo Clin. Proc. – 1994; 69 (6): 539–47.
  12. Drossman D. The Functional Gastrointestinal Disorders and the Rome III Process // Gastroentrology. – 2006; 130 (5): 1377–90.
  13. Fletcher J., Wirz A., Young J. et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal // Gastroenterology. – 2001; 121 (4): 775–83.
  14. Beaumont H., Bennink R., de Jong J. et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD // Gut. – 2010; 59 (4): 441–51.
  15. Kahrilas P., McColl K., Fox M. et al. The acid pocket: a target for treatment in reflux disease? // Am. J. Gastroenterol. – 2013; 108 (7): 1058–64.
  16. Rohof W., Bennink R., Boeckxstaens G. Effect of PPIs on the size, position and acidity of the postprandial acid pocket // Gastroenterology. – 2012; 142: 92.
  17. Corvaglia L., Aceti A., Mariani E. et al. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants // Aliment. Pharmacol. Ther. – 2011; 33 (4): 466–70.
  18. Thomas E., Wade A., Crawford G. et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) – a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease // Aliment. Pharmacol. Ther. – 2014; 39 (6): 595–602.
  19. Sun J., Yang C., Zhao H. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China // Aliment. Pharmacol. Ther. – 2015; 42 (7): 845–54.